FASN and breast cancer: Studies have demonstrated that Food and Drug Administration (FDA)-approved proton pump inhibitors can effectively inhibit FASN and sensitize breast cancer cells to the doxorubicin and ionizing radiation therapy in a large breast cancer patient cohort [114].